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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of parathyroidectomy for adults with PHPT. We will also compare the effects of different types of parathyroidectomy
on people with PHPT.
B A C K G R O U N D
Description of the condition
Primary hyperparathyroidism
(PHPT) is an endocrine disorder that affects approximately 1%
of the adult population, and is the third most common endocrine
disorder after diabetes mellitus and hypothyroidism (Best 2017).
Incidence of the disease increases in older age groups, with the
highest prevalence being about 2% in postmenopausal women in
the USA (Ning 2009). The disease is caused by a benign parathy-
roid adenoma in approximately 80% of cases, as a consequence of
multigland disorder (multiple adenomas or multigland hyperpla-
sia) in 15% to 20% of cases, or, in rare cases, a parathyroid carci-
noma (Bilezikian 2017). Usually PHPT is associated with hyper-
calcaemia, elevated or high normal parathyroid hormone (PTH)
levels, hypercalciuria, renal stones and bone demineralisation that
results in osteopenia or osteoporosis. Although most people with
the disease remain asymptomatic prior to the diagnosis with only
mild disease, some people may present with symptomatic hyper-
calcaemia, dehydration leading to acute kidney injury, fragility
fractures from osteoporosis, hypertension or chronic kidney dis-
ease that prompts clinicians to investigate for PHPT. Elevated
PTH levels result in increased bone turnover and skeletal dem-
ineralisation. Increased bone turnover leads on to gradual loss of
cortical bone mineral density with relative sparing of trabecular
bones, and results in predominant osteopenia or osteoporosis of
the lumbar spine, neck of femur and forearm bones (Khan 2017;
Silverberg 2014). This bone mineral density loss can lead to bone
fractures of these sites even with minimal trauma (fragility frac-
tures) which increases morbidity and premature mortality risk, es-
pecially in older people with the disease. Alterations in calcium
metabolism and bone turnover result in hypercalcaemia, hyper-
calciuria and nephrolithiasis in a significant proportion of people
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with PHPT. Recent data suggest a prevalence of renal stone dis-
ease in 10% to 20% of individuals with PHPT (Cipriani 2015;
Verdelli 2017). Furthermore, hypertension is found in 40% to
65% of people with PHPT, which increases the risk of cardio-
vascular morbidity and premature mortality (Pepe 2017). PHPT
has also been associated with psychoneurological and cognitive
dysfunction (Kreidieh 2013; Trombetti 2016). In a proportion of
individuals with PHPT serum calcium levels may be consistently
in the normal laboratory range and these cases constitute nor-
mocalcaemic PHPT. The metabolic and end organ complications
in these individuals may be similar to those with classical PHPT
(Yener 2016). Overall, PHPT is associated with excess morbidity
risk and higher risk of premature mortality.
Description of the intervention
Surgical removal of abnormal parathyroid tissue (parathyroidec-
tomy) is the optimal treatment for people with proven PHPT. Op-
erative removal of the diseased parathyroid gland(s) removes the
source of excess PTH production, and thereby cures the disease in
most individuals (Kreidieh 2013). International consensus recom-
mends that all people with symptomatic PHPT should be consid-
ered for parathyroidectomy, and identifies parathyroidectomy as
an effective treatment to improve end organ complications, such as
abnormal bone mineral density, renal stone disease and renal func-
tions, and potentially cardiovascular outcomes and neurocogni-
tive functions (Silverberg 2014). This consensus also recommends
parathyroidectomy for the following groups with PHPT.
• People who develop the disease before the age of 50 years.
• Serum calcium levels greater than 1 mg/dL (0.25 mmol/L)
of the upper limit of normal laboratory reference range.
• Bone mineral density T-score of −2.5 or more at lumbar
spine, femoral neck, total hip or distal 1/3rd of radius for
postmenopausal women or males greater than 50 years.
• Low trauma fragility fracture.
• A glomerular filtration rate of less than 60 mL/min, renal
stones, nephrocalcinosis or high risk for renal stone formation in
those with urine calcium of more than 400 mg/day.
Parathyroidectomy is also associated with improvements in func-
tional capacity and health-related quality of life even in asymp-
tomatic individuals with PHPT (Ambrogini 2007; Morris 2010).
Surgeons employ different techniques for parathyroidectomy de-
pending on the type of involvement of the parathyroid glands.
All individuals with the diagnosis of PHPT should be evalu-
ated by parathyroid imaging studies in the attempt to localise
the disease pathology in one or more of the parathyroid glands
before considering surgical intervention. This approach enables
the surgeons to decide the optimal surgical approach for parathy-
roidectomy. Localisation studies to identify the diseased parathy-
roid gland(s) include ultrasonography, nuclear medicine-based
parathyroid scintigraphy, and multiphase or four-dimensional
computed tomography (Kuzminski 2018). Minimally invasive
parathyroidectomy is the ideal treatment option for patients with a
well localised disease identified by preoperative parathyroid imag-
ing (Khan 2017). Open surgery by parathyroid exploration be-
comes necessary among patients with non-localisation of ade-
noma(s) in parathyroid imaging. Although dependent on the sur-
gical expertise, both focused, image-guided, minimally invasive
parathyroidectomy and bilateral neck exploration can achieve high
cure rates in people with PHPT (Wilhelm 2016).
Minimally invasive parathyroidectomy
Common approaches for minimally invasive parathyroidectomy
involve open focal mini-incision (70% of cases), video-assisted ap-
proach (~20% of cases) or total endoscopic approach (~10% of
cases), depending on clinical situation and the surgeons’ ability
to perform the technique (Brunaud 2016; Taieb 2013). Gagner
1996 first described total endoscopic parathyroidectomy with sub-
sequent refinements of the technique to the current day surgical
practice. Video-assisted parathyroidectomy, first described in 1997
(Miccoli 1997), is also performed partially with the help of an en-
doscope but does not use gas to view the surgical field as in the other
techniques. An extra-cervical endoscopic approach that avoids a
neck scar, through the chest wall, breast, oral cavity, retro-auricular
region and axilla, is also occasionally used for minimally invasive
parathyroidectomy. Robotic parathyroidectomy that places a com-
puter interface between patient and surgeon to optimise the feasi-
bility and quality of surgery is a new approach in minimally inva-
sive parathyroidectomy (Garas 2015). Intraoperative PTH moni-
toring helps the surgeons to verify successful surgery during min-
imally invasive parathyroidectomy. Intraoperative PTH monitor-
ing involves measurement of PTH, generally through peripheral
veins, pre-incision, pre-gland ligation, and at 5, 10 and 20 minutes
postgland ligation during the minimally invasive parathyroidec-
tomy. A reduction in PTH level of more than 50 % from the
highest baseline value at 10 minutes postgland ligation is generally
considered as evidence for adequate gland excision (Barczynski
2009). Intraoperative PTH monitoring has been recently reported
to help prediction of successful parathyroidectomy with very high
precision, and also to identify multiglandular disease and parathy-
roid cancer (Dobrinja 2017).
Bilateral neck exploration for parathyroidectomy
Until the late 1970s bilateral neck exploration surgical technique
was the standard approach for parathyroidectomy in people with
PHPT, which was successful in about 97% of cases and with re-
ported complication rates of 1% to 2% (Brunaud 2016). The
surgery involves exploration of all the four parathyroid glands to
locate the abnormal gland (the adenoma) usually under general
anaesthesia with a large neck incision. Bilateral neck exploration is
now utilised only when preoperative localisation of the adenoma is
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not possible, in case of discordant localisation studies in parathy-
roid imaging, familial or genetic disorders of PHPT, and concomi-
tant thyroid disease. The procedure may also be performed by a
minimal incision or video-assisted endoscopic approach (Alesina
2013; Kreidieh 2013).
Adverse effects of the intervention
In general, parathyroidectomy is associated with low rates of sur-
gical and postoperative complications. A recent systematic review
of 82 observational studies and sic randomised controlled trials
(RCTs) at moderate risk of bias concluded that minimally inva-
sive parathyroidectomy and bilateral neck exploration are both
effective techniques for parathyroidectomy in the treatment of
PHPT, with the safety profile of minimally invasive parathyroidec-
tomy being slightly superior to bilateral neck exploration (Singh
2016a). This publication also revealed a statistically significant
increased risk of hypocalcaemia in the bilateral neck exploration
group compared with the minimally invasive parathyroidectomy
group (14% vs 2.3%, P < 0.001). Statistically significant lower
risk of laryngeal nerve injury was also evident with minimally in-
vasive parathyroidectomy compared to bilateral neck exploration
(0.3% vs 0.9%). However, the risk of infection (0.5% vs 0.5%)
and premature mortality (0.1% vs 0.5%) were comparable in both
groups. Another important complication of parathyroidectomy is
hematoma formation that may present with neck pain, respira-
tory distress, dysphagia and increased drainage from the surgical
wound (Kreidieh 2013). Open drainage of the hematoma may
be necessary in some people. Hungry bone syndrome associated
with severe postoperative hypocalcaemia requiring intense med-
ical management can complicate some cases of severe PHPT af-
ter parathyroidectomy (Witteveen 2013). Although postoperative
hypoparathyroidism with symptomatic hypocalcaemia is usually
transient, some cases may warrant long-term follow-up and med-
ical management (Fyrsten 2016).
Persistent PHPT with development of postoperative hypercal-
caemia within six months of parathyroidectomy occurs in up to 5%
of individuals because of incomplete removal of abnormal parathy-
roid tissue (Silverberg 2014). Recurrent disease, development of
new onset PHPT, can also occur in up to 8% of individuals with
sporadic parathyroid adenomas after 3 to 11 years. The abnormal
glands are often located in eutopic positions (rather than an ectopic
gland) that should be identified by localisation studies before re-
operations (Khan 2017; Silverberg 2014). The reoperation is best
performed as minimally invasive parathyroidectomy if the tumour
is localised or as unilateral exploration on the other side that has
not been explored previously. Reported success rate of reoperation
exceeds 90% especially when preoperative localisation of the ab-
normal parathyroid tissue is possible and when parathyroidectomy
is coupled with intraoperative PTH assay. However, postoperative
complications including hypoparathyroidism are higher in people
undergoing reoperation (Khan 2017; Silverberg 2014).
How the intervention might work
As PHPT is a consequence of excess production of PTH from one
or more of the parathyroid glands, complete surgical removal of
the abnormal parathyroid tissue is expected to cure the disease.
Biochemical evidence of normalisation of raised PTH level with
resolution of hypercalcaemia in people with PHPT after parathy-
roidectomy usually indicate cure of the disease. In individuals with
normocalcaemic PHPT, normalisation of elevated PTH levels usu-
ally indicate cure. Regardless of the surgical technique used, high
cure rates were observed in patients who underwent successful
parathyroidectomy (Khan 2017; Kreidieh 2013; Silverberg 2014;
Singh 2016a). Although there is a small risk of recurrence of the
disease even in sporadic cases of PHPT, the health benefits of suc-
cessful parathyroidectomy observed during postoperative follow-
up period form clear rationale for recommending this treatment
option for appropriately selected patients.
Why it is important to do this review
The prevalence of PHPT steadily increases with age, and older
individuals tend to develop much more complications related to
the disease compared to younger individuals (Oltmann 2014).
Because of the availability of better healthcare, the proportion of
elderly individuals has increased markedly in the global popula-
tion in recent years. The cumulative risk of adverse hormonal ef-
fects from elevated PTH levels on target organs increase with the
duration of PHPT, and older age-groups are more vulnerable to
the end-organ complications related to the disease, such as osteo-
porosis, kidney disease, cognitive dysfunction and cardiovascular
morbidity (Bilezikian 2017). Increased healthcare burden and the
related economic loss are the consequences of such complications.
Parathyroidectomy has been shown to improve bone-related health
outcomes in PHPT in multiple observational studies and RCTs
(Hansen 2012; Khosla 1999; Koumakis 2013; Lundstam 2015;
Nilsson 2017; Vestergaard 2000). Other health benefits, such as
prevention of deterioration of renal functions (Tassone 2015),
improvement of cardiovascular morbidity (Best 2017; McMahon
2015), and better health-related quality of life (Aberg 2015), have
been demonstrated following parathyroidectomy in patients with
PHPT.
Although there are a few recent systematic reviews on this topic
(Cheng 2015; McMahon 2015; Singh 2016a; Singh 2016b), and
two previous Cochrane protocols suggest moderate health benefits
of parathyroidectomy in people with PHPT in terms of improve-
ments in bone mineral density, cognitive functions and health-
related quality of life (Ramakant 2017; Smith 2017), there are
still uncertainties on the overall health benefits of parathyroidec-
tomy, the appropriate patient categories that benefit most from
surgery, the severity of hyperparathyroidism for which parathy-
roidectomy should definitely be the choice, and the economic im-
pact of surgery over medical therapy. Therefore, there is a need
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to compile the latest RCT evidence to examine the benefits of
parathyroidectomy as a treatment option for the management of
PHPT.
O B J E C T I V E S
To assess the effects of parathyroidectomy for adults with PHPT.
We will also compare the effects of different types of parathy-
roidectomy on people with PHPT.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include RCTs.
Types of participants
We will limit participants of interest to adults (aged 18 years or
more) with PHPT who underwent parathyroidectomy for the first
time.
Diagnostic criteria for PHPT
We will define PHPT (Bilezikian 2017), by one or more of the
following.
• Elevated or high normal PTH levels with elevated serum
calcium levels above the normal laboratory reference values.
• Elevated serum PTH with normal calcium levels and
exclusion of secondary causes for elevation of PTH (mainly
decreased calcium intake, vitamin D deficiency, renal
insufficiency and hypercalciuria of renal origin).
• Exclusion of secondary causes for hyperparathyroidism such
as chronic renal insufficiency and vitamin D deficiency.
Types of interventions
We plan to investigate the following comparisons of intervention
versus control/comparator.
Intervention
(a) Minimally invasive parathyroidectomy (focal mini-incision,
video-assisted approach, totally-endoscopic or robotic approach).
(b) Parathyroidectomy by bilateral surgical neck exploration.
Comparator
Participants compared with (a) or (b) managed by:
• biochemical, clinical and imaging follow-up without
surgical interventions for any reason, such as personal preference,
decision by treating physicians or contraindications for surgery
from other serious medical conditions.
• pharmacotherapy such as bisphosphonates and calcium
lowering drugs (calcimimetics) without parathyroidectomy.
We will investigate different parathyroidectomy surgical tech-
niques with each other. Concomitant interventions must be the
same in both the intervention and comparator groups to establish
fair comparisons. If a trial includes multiple arms, we will include
any trial arm that meets the inclusion criteria.
Minimum duration of follow-up
Minimal duration of follow-up will be six months after the surgical
procedure. We will define any follow-up period going beyond the
original time frame for the primary outcome measure as specified
in the power calculation of the trial’s protocol as an extended
follow-up period (also called open-label extension study) (Buch
2011; Megan 2012).
Summary of specific exclusion criteria
We will exclude trials of the following category of participants.
• Participants with secondary hyperparathyroidism
• Participants with tertiary hyperparathyroidism
• Participants with different types of hyperparathyroidism
with no separate reporting of results by type
• Duration of follow-up less than six months
• Trials in participants younger than 18 years
Types of outcome measures
We will not exclude a trial if it fails to report one or several of our
primary or secondary outcome measures. If a trial does not report
any of these primary or secondary outcomes, we will not include
the trial but will provide some basic information in an additional
table.
We will investigate the following outcomes using the methods and
time points specified below.
Primary outcomes
• Cure of PHPT
• Morbidity related to PHPT
• Adverse events of surgery
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Secondary outcomes
• All-cause mortality
• Health-related quality of life
• Hospitalisation for correction of hypercalcaemia or acute
renal impairment
• Socioeconomic effects
Method of outcome measurement
• Cure of PHPT: defined by improvement of hypercalcaemia
and elevated PTH levels to the normal laboratory reference
values.
• Morbidity related to PHPT such as improvement or lack of
progression of osteoporosis osteopenia after parathyroidectomy,
lack of progression of kidney dysfunction or renal stone disease,
improvement or lack of progression of cognitive function,
improvement or lack of worsening of cardiovascular disease.
• Adverse events of surgery: such as postoperative bleeding,
infections, hypocalcaemia and speech problems.
• All-cause mortality: defined as death from any cause.
• Health-related quality of life: evaluated by a validated
instrument such as medical outcomes study Short Form Survey
36 (SF-36);
• Hospitalisation for correction of severe hypercalcaemia
(calcium level more than 3.0 mmol/L) or acute renal impairment
(requiring intravenous hydration or dialysis).
• Socioeconomic effects: such as direct costs defined as
admission or readmission rates, average length of stay, visits to
general practitioner, emergency hospital visits, medication
consumption, indirect costs defined as resources lost due to
illness by the participant or their family member.
Timing of outcome measurement
• Adverse events, all-cause mortality: measured at any time
after participants were randomised to intervention or comparator
groups.
• Health-related quality of life, socioeconomic effects: up to
six months will be defined as short-term and longer than six
months will be defined as long term.
• Cure of PHPT: measured by normal calcium and PTH
levels at six months or later after participants were randomised to
intervention or comparator groups.
• Morbidity related to PHPT: measured at six months or later
after participants were randomised to intervention or comparator
groups.
• Hospitalisation with hypercalcaemia or renal impairment:
measured within six months after participants were randomised
to intervention or comparator groups.
Search methods for identification of studies
Electronic searches
We will search the following sources from the inception of each
database to the specified date and will place no restrictions on the
language of publication.
• Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies Online
(CRSO).
• MEDLINE Ovid (Epub Ahead of Print, In-Process &
Other Non-Indexed Citations, Ovid MEDLINE Daily and
Ovid MEDLINE; from 1946 onwards).
• LILACS (Latin American and Caribbean Health Science
Information database).
• ClinicalTrials.gov (www.clinicaltrials.gov).
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (www.who.int/trialsearch/).
We will not include Embase in our search, as RCTs indexed in
Embase are now prospectively added to CENTRAL via a highly
sensitive screening process (CENTRAL 2018).
We will continuously apply a MEDLINE (via Ovid SP) email
alert service established by the Cochrane Metabolic and Endocrine
Disorders (CMED) Group to identify newly published trials using
the same search strategy as described for MEDLINE (Appendix 1).
After we submit the review draft for editorial approval, the CMED
Group will perform a complete search update on all databases
available at the editorial office and will send the results to the
review authors. Should we identify new trials for inclusion, we will
evaluate these and incorporate the findings into our review (Beller
2013).
Searching other resources
We will try to identify other potentially eligible trials or ancillary
publications by searching the reference lists of included trials, sys-
tematic reviews, meta-analyses and health technology assessment
reports. In addition we will contact authors of included trials to
identify any additional information on the retrieved trials and es-
tablish whether we may have missed further trials.
We will not use abstracts or conference proceedings for data ex-
traction unless full data are available from trial authors because this
information source does not fulfil the CONSORT requirements
which consist of “an evidence-based, minimum set of recom-
mendations for reporting randomised trials” (CONSORT 2016;
Scherer 2007). We will present information on abstracts or con-
ference proceedings in the ’Characteristics of studies awaiting clas-
sification’ table.
Data collection and analysis
5Parathyroidectomy for adults with primary hyperparathyroidism (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Selection of studies
After removal of duplicates, two review authors (JMP and AKV)
will independently screen the abstract and title of every record re-
trieved by the searches. We will obtain the full-text of all potentially
eligible relevant records, and will screen them for eligibility. We
will resolve any disagreements through consensus or by recourse
to a third review author (RS). If we cannot resolve a disagreement,
we will categorise the trial as a ’study awaiting classification’ and
will contact the trial authors for clarification. We will present an
adapted PRISMA flow diagram to show the process of trial selec-
tion (Liberati 2009). We will list all articles excluded after full-text
assessment in a ’Characteristics of excluded studies’ table and will
provide the reasons for exclusion.
Data extraction and management
Two review authors (JMP and RS) will independently extract the
data from trials that fulfil our inclusion criteria to identify key
participant and intervention characteristics. We will describe in-
terventions by use of the ’template for intervention description
and replication’ (TIDieR) checklist (Hoffmann 2014; Hoffmann
2017).
We will report data on efficacy outcomes and adverse events using
standardised data extraction sheets from the CMED Group. We
will resolve any disagreements by discussion or, if required, we will
consult a third review author (AKV).
We will provide information about potentially relevant ongoing
trials, including the trial identifiers, in the table ’Characteristics of
ongoing trials’ and in a joint appendix ’Matrix of trial endpoint
(publications and trial documents)’. We will try to find the proto-
col for each included trial and we will report primary, secondary
and other outcomes in comparison with data in publications in a
joint appendix.
We will email all authors of included trials to enquire whether
they would be willing to answer questions regarding their trials.
We will present the results of this survey in an appendix. We will
thereafter seek relevant missing information on the trial from the
primary trial author(s), if required.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents or
multiple reports of a primary trial, we will maximise the informa-
tion yield by collating all available data, and we will use the most
complete data set aggregated across all known publications. We
will list duplicate publications, companion documents, multiple
reports of a primary trial, and trial documents of included trials
(such as trial registry information) as secondary references under
the study ID of the included trial. Furthermore, we will also list
duplicate publications, companion documents, multiple reports
of a trial, and trial documents of excluded trials (such as trial reg-
istry information) as secondary references under the study ID of
the excluded trial.
Data from clinical trials registers
If data from included trials are available as study results in clinical
trials registers, such as ClinicalTrials.gov or similar sources, we will
make full use of this information and will extract the data. If there
is also a full publication of the trial, we will collate and critically
appraise all available data. If an included trial is marked as a com-
pleted study in a clinical trial register but no additional informa-
tion (study results, publication or both) is available, we will add
this trial to the ’Characteristics of studies awaiting classification’
table.
Assessment of risk of bias in included studies
Two review authors (JMP and IML) will independently assess the
risk of bias of each included trial. We will resolve any disagreements
by consensus or by consulting a third review author (AKV). In
the case of disagreement, we will consult the rest of the review
author team and we will make a judgement based on consensus.
If adequate information is unavailable from the publications, trial
protocols or other sources, we will contact the trial authors for
more detail to request missing data on ’Risk of bias’ items.
We will use the Cochrane ’Risk of bias’ assessment tool (Higgins
2017), assigning assessments of low, high or unclear risk of bias (for
details see Appendix 2; Appendix 3). We will evaluate individual
bias items as described in the Cochrane Handbook for Systematic
Reviews of Interventions according to the criteria and associated
categorisations contained therein (Higgins 2017).
Summary assessment of risk of bias
We will present a ’Risk of bias’ graph and a ’Risk of bias’ summary
figure.
We will distinguish between self-reported, investigator-assessed
and adjudicated outcome measures.
We will consider the following self-reported outcomes.
• Health-related quality of life
• Adverse events of surgery
We will consider the following outcomes to be investigator-as-
sessed.
• Cure of PHPT
• Morbidity related to PHPT
• All-cause mortality
• Adverse events of surgery
• Hospitalisation with hypercalcaemia or renal impairment
• Socioeconomic effects
Risk of bias for a trial across outcomes
Some risk of bias domains, such as selection bias (sequence gener-
ation and allocation sequence concealment), affect the risk of bias
across all outcome measures in a trial. In the case of high risk of
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selection bias, we will mark all endpoints investigated in the asso-
ciated trial as being at high risk. Otherwise, we will not perform
a summary assessment of the risk of bias across all outcomes for a
trial.
Risk of bias for an outcome within a trial and across domains
We will assess the risk of bias for an outcome measure by including
all entries relevant to that outcome (i.e. both trial-level entries and
outcome-specific entries). We consider low risk of bias to denote
a low risk of bias for all key domains, unclear risk to denote an
unclear risk of bias for one or more key domains and high risk to
denote a high risk of bias for one or more key domains.
Risk of bias for an outcome across trials and across domains
These are the main summary assessments that we will incorporate
into our judgments about the certainty of evidence in the ’Sum-
mary of findings’ tables. We will define outcomes as at low risk of
bias when most information comes from trials at low risk of bias,
unclear risk when most information comes from trials at low or
unclear risk of bias, and high risk when a sufficient proportion of
information comes from trials at high risk of bias.
Measures of treatment effect
When at least two included trials are available for a comparison and
a given outcome, we will try to express dichotomous data as a risk
ratio (RR) or odds ratio (OR) with 95% confidence intervals (CIs).
For continuous outcomes measured on the same scale (e.g. weight
loss in kg), we will estimate the intervention effect using the mean
difference (MD) with 95% CIs. For continuous outcomes that
measure the same underlying concept (e.g. health-related quality
of life) but use different measurement scales, we will calculate the
standardised mean difference (SMD). We will express time-to-
event data as a hazard ratio (HR) with 95% CIs.
Unit of analysis issues
We will take into account the level at which randomisation oc-
curred, such as for cross-over trials, cluster-randomised trials and
multiple observations for the same outcome. If more than one
comparison from the same trial is eligible for inclusion in the same
meta-analysis, we will either combine groups to create a single
pair-wise comparison or appropriately reduce the sample size so
that the same participants do not contribute data to the meta-
analysis more than once (splitting the ’shared’ group into two or
more groups). While the latter approach offers some solution to
adjusting the precision of the comparison, it does not account for
correlation arising from the same set of participants being in mul-
tiple comparisons (Higgins 2011).
We will attempt to re-analyse cluster-RCTs that have not appropri-
ately adjusted for potential clustering of participants within clus-
ters in their analyses. The variance of the intervention effects will
be inflated by a design effect. Calculation of a design effect in-
volves estimation of an intracluster correlation coefficient (ICC).
We will obtain estimates of ICCs by contacting trial authors or
by imputing the ICC values by using either estimates from other
included trials that report ICCs or external estimates from empir-
ical research (e.g. Bell 2013). We plan to examine the impact of
clustering using sensitivity analyses.
Dealing with missing data
If possible, we will obtain missing data from the authors of the
included trials. We will carefully evaluate important numerical
data such as screened, randomly assigned participants as well as
intention-to-treat, and as-treated and per-protocol populations.
We will investigate attrition rates (e.g. dropouts, losses to follow-
up, withdrawals), and we will critically appraise issues concerning
missing data and use of imputation methods (e.g. last observation
carried forward).
In trials where the standard deviation (SD) of the outcome is not
available at follow-up or we cannot recreate it, we will standardise
by the mean of the pooled baseline SD from those trials that
reported this information.
Where included trials do not report means and SDs for outcomes
and we do not receive the necessary information from trial authors,
we will impute these values by estimating the mean and variance
from the median, range and the size of the sample (Hozo 2005).
We will investigate the impact of imputation on meta-analyses
by performing sensitivity analyses, and we will report for every
outcome which trials had imputed SDs.
Assessment of heterogeneity
In the event of substantial clinical or methodological heterogene-
ity, we will not report trial results as the pooled effect estimate in
a meta-analysis.
We will identify heterogeneity (inconsistency) by visually inspect-
ing the forest plots and by using a standard Chi² test with a sig-
nificance level of α = 0.1 (Deeks 2017). In view of the low power
of this test, we will also consider the I² statistic, which quantifies
inconsistency across trials to assess the impact of heterogeneity on
the meta-analysis (Higgins 2002; Higgins 2003).
When we find heterogeneity, we will attempt to determine the
possible reasons for it by examining individual trial and subgroup
characteristics.
Assessment of reporting biases
If we include 10 or more trials that investigate a particular out-
come, we will use funnel plots to assess small-trial effects. Several
explanations may account for funnel plot asymmetry, including
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true heterogeneity of effect with respect to trial size, poor method-
ological design (and hence bias of small trials) and publication
bias (Sterne 2017). Therefore we will interpret the results carefully
(Sterne 2011).
Data synthesis
We plan to undertake (or display) a meta-analysis only if we judge
participants, interventions, comparisons and outcomes to be suf-
ficiently similar to ensure an answer that is clinically meaningful.
Unless good evidence shows homogeneous effects across trials of
different methodological quality, we will primarily summarise low
risk of bias data using a random-effects model (Wood 2008). We
will interpret random-effects meta-analyses with due considera-
tion to the whole distribution of effects and present a prediction
interval (Borenstein 2017a; Borenstein 2017b; Higgins 2009). A
prediction interval needs at least four trials to be calculated and
specifies a predicted range for the true treatment effect in an indi-
vidual trial (Riley 2011). For rare events such as event rates below
1%, we will use the Peto’s odds ratio method provided that there
is no substantial imbalance between intervention and comparator
group sizes and intervention effects are not exceptionally large.
In addition, we will perform statistical analyses according to the
statistical guidelines presented in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Deeks 2017).
Subgroup analysis and investigation of heterogeneity
We expect the following characteristics to introduce clinical het-
erogeneity, and we plan to carry out the following subgroup anal-
yses including investigation of interactions (Altman 2003).
• Different surgical techniques
• Severity of PHPT
• Difference in the demographics of trial population such as
gender, age and ethnic differences
Sensitivity analysis
We plan to perform sensitivity analyses to explore the influence of
the following factors (when applicable) on effect sizes by restricting
analysis to the following.
• Published trials.
• Effect of risk of bias, as specified in the ’Assessment of risk
of bias in included studies’ section.
• Very long or large trials to establish the extent to which they
dominate the results.
• Using the following filters: diagnostic criteria, imputation,
language of publication, source of funding (industry versus
other) or country.
We will also test the robustness of results by repeating the analyses
using different measures of effect size (RR, OR, etc.) and different
statistical models (fixed-effect and random-effects models).
Certainty of the evidence
We will present the overall certainty of evidence for each outcome
specified below, according to the GRADE approach, which takes
into account issues related not only to internal validity (risk of bias,
inconsistency, imprecision, publication bias) but also to external
validity, such as directness of results. Two review authors (JMP
and IML) will independently assess the certainty of evidence for
each outcome. We will resolve any differences in assessment by
discussion or consulting a third review author (RS).
We will include an appendix entitled ’Checklist to aid consistency
and reproducibility of GRADE assessments’, to help with stan-
dardisation of the ’Summary of findings’ tables (Meader 2014).
Alternatively, we will use the GRADEpro Guideline Development
Tool (GDT) software and will present evidence profile tables as
an appendix (GRADEpro GDT 2015). We will present results for
the outcomes as described in the ’Types of outcome measures’ sec-
tion. If meta-analysis is not possible, we will present the results in a
narrative format in the ’Summary of findings’ table. We will justify
all decisions to downgrade the quality of trials using footnotes,
and we will make comments to aid the reader’s understanding of
the Cochrane Review where necessary.
’Summary of findings’ table
We will present a summary of the evidence in a ’Summary of find-
ings’ table. This will provide key information about the best esti-
mate of the magnitude of the effect, in relative terms and as abso-
lute differences, for each relevant comparison of alternative man-
agement strategies, numbers of participants and trials addressing
each important outcome and a rating of overall confidence in effect
estimates for each outcome. We will create the ’Summary of find-
ings’ table based on the methods described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Schünemann 2017)
using Review Manager 5 (RevMan 5) table editor (RevMan 2014).
We will report the following outcomes, listed according to prior-
ity.
• Cure of PHPT
• Morbidity related to PHPT
• All-cause mortality
• Adverse events of surgery
• Health-related quality of life
• Hospitalisation with hypercalcaemia or renal impairment
• Socioeconomic effects.
A C K N O W L E D G E M E N T S
We thank the CMED Information Specialist, Maria-Inti Metzen-
dorf, for developing the search strategies.
8Parathyroidectomy for adults with primary hyperparathyroidism (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
Additional references
Aberg 2015
Aberg V, Norenstedt S, Zedenius J, Sääf M, Nordenström J,
Pernow Y, et al. Health-related quality of life after successful
surgery for primary hyperparathyroidism: no additive effect
from vitamin D supplementation: results of a double-blind
randomized study. European Journal of Endocrinology 2015;
172(2):181–7.
Alesina 2013
Alesina PF, Hinrichs J, Heuer M, Hofmeister S, Meier
B, Walz MK. Feasibility of video-assisted bilateral neck
exploration for patients with primary hyperparathyroidism
and failed or discordant localization studies. Langenbeck’s
Archives of Surgery 2013;398(1):107–11.
Altman 2003
Altman DG, Bland JM. Interaction revisited: the difference
between two estimates. BMJ 2003;326(7382):219.
[PUBMED: 12543843]
Ambrogini 2007
Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti
C, Viccica G, et al. Surgery or surveillance for mild
asymptomatic primary hyperparathyroidism: a prospective,
randomized clinical trial. Journal of Clinical Endocrinology
and Metabolism 2007;92(8):3114–21.
Barczynski 2009
Barczynski M, Konturek A, Hubalewska-Dydejczyk A,
Cichon S, Nowak W. Evaluation of Halle, Miami, Rome,
and Vienna intraoperative iPTH assay criteria in guiding
minimally invasive parathyroidectomy. Langenbeck’s Archives
of Surgery 2009;394(5):843–9.
Bell 2013
Bell ML, McKenzie JE. Designing psycho-oncology
randomised trials and cluster randomised trials: variance
components and intra-cluster correlation of commonly
used psychosocial measures. Psychooncology 2013;22(8):
1738–47.
Beller 2013
Beller EM, Chen JK, Wang UL, Glasziou PP. Are systematic
reviews up-to-date at the time of publication?. Systematic
Reviews 2013;2:36. [2046–4053: (Electronic)]
Best 2017
Best CAE, Krishnan R, Malvankar-Mehta MS, MacNeil
SD. Echocardiogram changes following parathyroidectomy
for primary hyperparathyroidism: a systematic review and
meta-analysis. Medicine 2017;96(43):e7255.
Bilezikian 2017




Borenstein M, Higgins JP, Hedges LV, Rothstein HR.
Basics of meta-analysis: I² is not an absolute measure of
heterogeneity. Research Synthesis Methods 2017;8(1):5–18.
Borenstein 2017b
Borenstein M. Prediction intervals. www.meta-
analysis.com/prediction (accessed 3 July 2017).
Boutron 2014
Boutron I, Altman DG, Hopewell S, Vera-Badillo F,
Tannock I, Ravaud P. Impact of spin in the abstracts of
articles reporting results of randomized controlled trials in
the field of cancer: the SPIIN randomized controlled trial.
Journal of Clinical Oncology 2014;32(36):4120–6.
Brunaud 2016
Brunaud L, Li Z, Van Den Heede K, Cuny T, Van Slycke
S. Endoscopic and robotic parathyroidectomy in patients
with primary hyperparathyroidism. Gland Surgery 2016;5
(3):352–60.
Buch 2011
Buch MH, Aletaha D, Emery P, Smolen JS. Reporting of
long-term extension studies: lack of consistency calls for
consensus. Annals of the Rheumatic Diseases 2011;70(6):
886–90.
CENTRAL 2018
CENTRAL creation details. www.cochranelibrary.com/
help/central-creation-details.html (accessed 15 March
2018).
Cheng 2015
Cheng SP, Lee JJ, Liu TP, Yang PS, Liu SC, Hsu YC,
et al. Quality of life after surgery or surveillance for
asymptomatic primary hyperparathyroidism: a meta-
analysis of randomized controlled trials. Medicine 2015;94
(23):e931.
Cipriani 2015
Cipriani C, Biamonte F, Costa AG, Zhang C, Biondi
P, Diacinti D, et al. Prevalence of kidney stones and
vertebral fractures in primary hyperparathyroidism using
imaging technology. Journal of Clinical Endocrinology and
Metabolism 2015;100(4):1309–15.
CONSORT 2016
The CONSORT statement. www.consort-statement.org
(accessed 19 May 2016).
Corbett 2014
Corbett MS, Higgins JP, Woolacott NF. Assessing baseline
imbalance in randomised trials: implications for the
Cochrane risk of bias tool. Research Synthesis Methods 2014;
5(1):79–85.
Deeks 2017
Deeks JJ, Higgins JPT, Altman DG (editors) on behalf
of the Cochrane Statistical Methods Group. Chapter
9: Analysing data and undertaking meta-analyses. In:
Higgins JPT, Churchill R, Chandler J, Cumpston MS
(editors), Cochrane Handbook for Systematic Reviews of
Interventions Version 5.2.0 (updated June 2017), Cochrane,
2017. Available from training.cochrane.org/handbook.
9Parathyroidectomy for adults with primary hyperparathyroidism (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dobrinja 2017
Dobrinja C, Santandrea G, Giacca M, Stenner E, Ruscio M,
de Manzini N. Effectiveness of intraoperative parathyroid
monitoring (ioPTH) in predicting a multiglandular or
malignant parathyroid disease. International Journal of
Surgery (London, England) 2017;41(Suppl 1):S26–33.
Fyrsten 2016
Fyrsten E, Norlén O, Hessman O, Stålberg P, Hellman
P. Long-term surveillance of treated hyperparathyroidism
for multiple endocrine neoplasia type 1: recurrence or
hypoparathyroidism?. World Journal of Surgery 2016;40(3):
615–21.
Gagner 1996
Gagner M. Endoscopic subtotal parathyroidectomy in
patients with primary hyperparathyroidism. British Journal
of Surgery 1996;83(6):875.
Garas 2015
Garas G, Holsinger FC, Grant DG, Athanasiou T, Arora
A, Tolley N. Is robotic parathyroidectomy a feasible and
safe alternative to targeted open parathyroidectomy for the
treatment of primary hyperparathyroidism?. International
Journal of Surgery (London, England) 2015;15:55–60.
GRADEpro GDT 2015 [Computer program]
GRADE Working Group, McMaster University.
GRADEpro GDT. Version accessed 19 April 2018.
Hamilton (ON): GRADE Working Group, McMaster
University, 2015.
Hansen 2012
Hansen S, Hauge EM, Rasmussen L, Jensen JE, Brixen
K. Parathyroidectomy improves bone geometry and
microarchitecture in female patients with primary
hyperparathyroidism: a one-year prospective controlled
study using high-resolution peripheral quantitative
computed tomography. Journal of Bone and Mineral
Research 2012;27(5):1150–8.
Higgins 2002
Higgins JPT, Thompson SG. Quantifying heterogeneity in a
meta-analysis. Statistics in Medicine 2002;21(11):1539–58.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analysis. BMJ 2003;327
(7414):557–60.
Higgins 2009
Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-
evaluation of random-effects meta-analysis. Journal of the
Royal Statistical Society: Series A (Statistics in Society) 2009;
172(1):137–59.
Higgins 2011
Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special
topics in statistics. In: Higgins JPT, Green S, editor
(s). Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Higgins 2017
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8:
Assessing risk of bias in included studies. In: Higgins JPT,
Churchill R, Chandler J, Cumpston MS (editors), Cochrane
Handbook for Systematic Reviews of Interventions Version
5.2.0 (updated June 2017), Cochrane, 2017. Available from
training.cochrane.org/handbook.
Hoffmann 2014
Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R,
Moher D, et al. Better reporting of interventions: template
for intervention description and replication (TIDieR)
checklist and guide. BMJ 2014;348:g1687.
Hoffmann 2017
Hoffmann TC, Oxman AD, Ioannidis JP, Moher D,
Lasserson TJ, Tovey DI, et al. Enhancing the usability of
systematic reviews by improving the consideration and
description of interventions. BMJ 2017;358:j2998.
Hozo 2005
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and
variance from the median, range, and the size of a sample.
BMC Medical Research Methodology 2005;5:13. DOI:
10.1186/1471-2288-5-13
Hróbjartsson 2013
Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B,
Hilden J, Boutron I, et al. Observer bias in randomized
clinical trials with measurement scale outcomes: a
systematic review of trials with both blinded and nonblinded
assessors. Canadian Medical Association Journal 2013;185
(4):E201–11.
Jones 2015
Jones CW, Keil LG, Holland WC, Caughey MC, Platts-
Mills TF. Comparison of registered and published outcomes
in randomized controlled trials: a systematic review. BMC
Medicine 2015;13:282. DOI: 10.1186/s12916-015-0520-3
Khan 2017
Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE,
Rejnmark L, et al. Primary hyperparathyroidism: review
and recommendations on evaluation, diagnosis, and
management. A Canadian and international consensus.
Osteoporosis International 2017;28(1):1–19. [PUBMED:
27613721]
Khosla 1999
Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS,
O’Fallon W, Riggs B. Primary hyperparathyroidism and the
risk of fracture: a population-based study. Journal of Bone
and Mineral Research 1999;14(10):1700–7.
Kirkham 2010
Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd
S, Smyth R, et al. The impact of outcome reporting bias
in randomised controlled trials on a cohort of systematic
reviews. BMJ 2010;340:c365. DOI: 10.1136/bmj.c365
Koumakis 2013
Koumakis E, Souberbielle JC, Sarfati E, Meunier M,
Maury E, Gallimard E, et al. Bone mineral density
evolution after successful parathyroidectomy in patients
10Parathyroidectomy for adults with primary hyperparathyroidism (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
with normocalcemic primary hyperparathyroidism. Journal
of Clinical Endocrinology and Metabolism 2013;98(8):
3213–20.
Kreidieh 2013
Kreidieh OI, Ahmadieh H, Akl EA, El-Hajj FG. Minimally
invasive parathyroidectomy guided by intraoperative
parathyroid hormone monitoring (IOPTH) and
preoperative imaging versus bilateral neck exploration for
primary hyperparathyroidism in adults. Cochrane Database
of Systematic Reviews 2013, Issue 10. DOI: 10.1002/
14651858.CD010787
Kuzminski 2018
Kuzminski SJ, Sosa JA, Hoang JK. Update in parathyroid
imaging. Magnetic Resonance Imaging Clinics of North
America 2018;26(1):151–66.
Liberati 2009
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche
PC, Ioannidis JPA, et al. The PRISMA statement for
reporting systematic and meta-analyses of studies that
evaluate interventions: explanation and elaboration.
PLOS Medicine 2009;6(7):e1000100. DOI: 10.1371/
journal.pmed.1000100
Lundstam 2015
Lundstam K, Heck A, Mollerup C, Godang K, Baranowski
M, Pernow Y, et al. Effects of parathyroidectomy versus
observation on the development of vertebral fractures in
mild primary hyperparathyroidism. Journal of Clinical
Endocrinology and Metabolism 2015;100(4):1359–67.
Mathieu 2009
Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P.
Comparison of registered and published primary outcomes
in randomized controlled trials. JAMA 2009;302:977–84.
McMahon 2015
McMahon DJ, Carrelli A, Palmeri N, Zhang C, DiTullio M,
Silverberg SJ, et al. Effect of parathyroidectomy upon left
ventricular mass in primary hyperparathyroidism: a meta-
analysis. Journal of Clinical Endocrinology and Metabolism
2015;100(12):4399–407.
Meader 2014
Meader N, King K, Llewellyn A, Norman G, Brown J,
Rodgers M, et al. A checklist designed to aid consistency
and reproducibility of GRADE assessments: development
and pilot validation. Systematic Reviews 2014;3:82.
Megan 2012
Megan B, Pickering RM, Weatherall M. Design, objectives,
execution and reporting of published open-label extension
studies. Journal of Evaluation in Clinical Practice 2012;18
(2):209–15.
Miccoli 1997
Miccoli P, Pinchera A, Cecchini G, Conte M, Bendinelli
C, Vignali E, et al. Minimally invasive, video-assisted
parathyroid surgery for primary hyperparathyroidism.
Journal of Endocrinological Investigation 1997;20(7):429–30.
Morris 2010
Morris GS, Grubbs EG, Hearon CM, Gantela S, Lee JE,
Evans DB, et al. Parathyroidectomy improves functional
capacity in “asymptomatic” older patients with primary
hyperparathyroidism: a randomized control trial. Annals of
Surgery 2010;251(5):832–7. [PUBMED: 20395857]
Nilsson 2017
Nilsson IL, Norenstedt S, Zedenius J, Pernow Y, Bränström
R. Primary hyperparathyroidism, hypercalciuria, and bone
recovery after parathyroidectomy. Surgery 2017;162(2):
429–36.
Ning 2009
Ning L, Sippel R, Schaefer S, Chen H. What is the clinical
significance of an elevated parathyroid hormone level after
curative surgery for primary hyperparathyroidism?. Annals
of Surgery 2009;249(3):469–72.
Oltmann 2014
Oltmann SC, Rajaei MH, Sippel RS, Chen H, Schneider
DF. Primary hyperparathyroidism across the ages:
presentation and outcomes. Journal of Surgical Research
2014;190(1):185–90.
Pepe 2017
Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F,
Minisola S. Cardiovascular manifestations of primary
hyperparathyroidism: a narrative review. European Journal
of Endocrinology 2017;177(6):R297–308.
Ramakant 2017
Ramakant P, Paul MJ, Paul TV, Rao SD, Abraham DT,
Uttley L, et al. Surgery versus surveillance for asymptomatic
(mild) primary hyperparathyroidism in adults 50 years or
older. Cochrane Database of Systematic Reviews 2017, Issue
7. DOI: 10.1002/14651858.CD010093.pub2
RevMan 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Riley 2011
Riley RD, Higgins JP, Deeks JJ. Interpretation of random
effects meta-analyses. BMJ 2011;342:d549.
Scherer 2007
Scherer RW, Langenberg P, von Elm E. Full publication of
results initially presented in abstracts. Cochrane Database
of Systematic Reviews 2007, Issue 2. DOI: 10.1002/
14651858.MR000005.pub3
Schünemann 2017
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE,
Glasziou P, Akl E, et al. on behalf of the Cochrane
GRADEing Methods Group and the Cochrane Statistical
Methods Group. Chapter 11: Completing ‘Summary
of findings’ tables and grading the confidence in or
quality of the evidence. In: Higgins JPT, Churchill R,
Chandler J, Cumpston MS (editors), Cochrane Handbook
for Systematic Reviews of Interventions Version 5.2.0
11Parathyroidectomy for adults with primary hyperparathyroidism (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(updated June 2017). Cochrane, 2017. Available from
training.cochrane.org/handbook.
Silverberg 2014
Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy
S, Cusano NE, et al. Current issues in the presentation of
asymptomatic primary hyperparathyroidism: proceedings
of the fourth international workshop. Journal of Clinical
Endocrinology and Metabolism 2014;99(10):3580–94.
Singh 2016a
Singh Ospina N, Maraka S, Rodriguez-Gutierrez R,
Espinosa de Ycaza AE, Jasim S, Gionfriddo M, et
al. Comparative efficacy of parathyroidectomy and
active surveillance in patients with mild primary
hyperparathyroidism: a systematic review and meta-
analysis. Osteoporosis International 2016;27(12):3395–407.
Singh 2016b
Singh Ospina NM, Rodriguez-Gutierrez R, Maraka S,
Espinosa de Ycaza AE, Jasim S, Castaneda-Guarderas A,
et al. Outcomes of parathyroidectomy in patients with
primary hyperparathyroidism: a systematic review and
meta-analysis. World Journal of Surgery 2016;40(10):
2359–77.
Smith 2017
Smith ME, Pfleiderer AG, Shamil E. Open minimally
invasive versus video-assisted minimally invasive
parathyroidectomy for primary hyperparathyroidism.
Cochrane Database of Systematic Reviews 2017, Issue 1.
DOI: 10.1002/14651858.CD012512
Sterne 2011
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau
J, et al. Recommendations for examining and interpreting
funnel plot asymmetry in meta-analyses of randomised
controlled trials. BMJ 2011;343:d4002.
Sterne 2017
Sterne JAC, Egger M, Moher D, Boutron I (editors).
Chapter 10: Addressing reporting biases. In: Higgins JPTG,
Churchill R, Chandler J, Cumpston MS (editors), Cochrane
Handbook for Systematic Reviews of Interventions Version
5.2.0 (updated June 2017), Cochrane, 2017. Available from
training.cochrane.org/handbook.
Taieb 2013
Taieb A, Seman M, Menegaux F, Tresallet C. Surgical
technique parathyroidectomy through a minimally
invasive gland-centred localized approach for primary
hyperparathyroidism. Journal of Visceral Surgery 2013;150
(6):403–6.
Tassone 2015
Tassone F, Guarnieri A, Castellano E, Baffoni C, Attanasio
R, Borretta G. Parathyroidectomy halts the deterioration of
renal function in primary hyperparathyroidism. Journal
of Clinical Endocrinology and Metabolism 2015;100(8):
3069–73.
Trombetti 2016
Trombetti A, Christ ER, Henzen C, Gold G, Brändle M,
Herrmann FR, et al. Clinical presentation and management
of patients with primary hyperparathyroidism of the
Swiss primary hyperparathyroidism cohort: a focus on
neuro-behavioral and cognitive symptoms. Journal of
Endocrinological Investigation 2016;39(5):567–76.
Verdelli 2017
Verdelli C, Corbetta S. Mechanisms in endocrinology:
kidney involvement in patients with primary
hyperparathyroidism: an update on clinical and molecular
aspects. European Journal of Endocrinology 2017;176(1):
R39–52.
Vestergaard 2000
Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen
P, Blichert-Toft M, Mosekilde L. Cohort study of
risk of fracture before and after surgery for primary
hyperparathyroidism. BMJ (Clinical research ed) 2000;321
(7261):598–602.
Wilhelm 2016
Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL,
Duh QY, et al. The American Association of Endocrine
Surgeons guidelines for definitive management of primary
hyperparathyroidism. JAMA Surgery 2016;151(10):
959–68.
Witteveen 2013
Witteveen JE, van Thiel S, Romijn JA, Hamdy NA. Hungry
bone syndrome: still a challenge in the post-operative
management of primary hyperparathyroidism: a systematic
review of the literature. European Journal of Endocrinology
2013;168(3):R45–53.
Wood 2008
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman
DG, et al. Empirical evidence of bias in treatment effect
estimates in controlled trials with different interventions
and outcomes: meta-epidemiological study. BMJ 2008;336
(7644):601–5.
Yener 2016
Yener Ozturk F, Erol S, Canat MM, Karatas S, Kuzu I,
Dogan Cakir S, et al. Patients with normocalcemic primary
hyperparathyroidism may have similar metabolic profile
as hypercalcemic patients. Endocrine Journal 2016;63(2):
111–8.
∗ Indicates the major publication for the study
12Parathyroidectomy for adults with primary hyperparathyroidism (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE (Ovid SP)
1. Hyperparathyroidism, Primary/
2. (primary adj3 hyperparathyroid*).tw.
3. Parathyroid Neoplasms/




8. (parathyroid* adj6 (surger* or surgic* or resection or excision or exploration)).tw
9. ((endoscop* or video or camera or minimally invasive or small incision or open) adj6 (surger* or surgic* or resection or excision
or exploration)).tw
10. or/6-9
11. 5 and 10
[Cochrane Handbook 2008 RCT filter - sensitivity maximizing version]
12. randomized controlled trial.pt.








21. exp animals/ not humans/
22. 20 not 21
23. 11 and 22
CENTRAL (Cochrane Library)
1. [mh “Hyperparathyroidism, Primary”]
2. (primary near/4 hyperparathyroid*):ti,ab,kw
3. [mh “Parathyroid Neoplasms”]




8. (parathyroid* near/7 (surgic* or resection or excision or exploration)):ti,ab,kw




12. #5 and #11
LILACS (iAHx)
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(Continued)
(MH:“Hyperparathyroidism, Primary” OR hyperparathyroid$ OR hiperparatireoid$ OR MH:“Parathyroid Neoplasms” OR
(parathyroid AND (adenoma$ or hyperplasia$ or neoplasm$ or tumor$))) AND (MH:“Parathyroidectomy” OR parathyroidectom$
OR paratiroidectom$ OR cirur$ OR surger$ or surgic$ OR resection OR excision OR exploration) + Filter “Controlled Clinical
Trial”
WHO ICTRP (Advanced search)
hyperparathyroid* AND parathyroidectom* OR
hyperparathyroid* AND surg* OR
parathyroid AND parathyroidectom* OR
parathyroid AND surg*
ClinicalTrials.gov (Advanced search)
Condition or disease: hyperparathyroidism OR parathyroid
Intervention/treatment: parathyroidectomy OR surgery OR surgical OR resection OR exploration
Appendix 2. ’Risk of bias’ assessment
’Risk of bias’ domains
Random sequence generation (selection bias due to inadequate generation of a randomised sequence)
For each included trial, we will describe the method used to generate the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups
• Low risk of bias: the trial authors achieved sequence generation using computer-generated random numbers or a random
numbers table. Drawing of lots, tossing a coin, shuffling cards or envelopes, and throwing dice are adequate if an independent
person performed this who was not otherwise involved in the trial. We will consider the use of the minimisation technique as
equivalent to being random.
• Unclear risk of bias: insufficient information about the sequence generation process.
• High risk of bias: the sequence generation method was non-random or quasi-random (e.g. sequence generated by odd or even
date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on
hospital or clinic record number; allocation by judgment of the clinician; allocation by preference of the participant; allocation
based on the results of a laboratory test or a series of tests; or allocation by availability of the intervention).
Allocation concealment (selection bias due to inadequate concealment of allocation prior to assignment)
We will describe for each included trial the method used to conceal allocation to interventions prior to assignment and we will assess
whether intervention allocation could have been foreseen in advance of or during recruitment or changed after assignment
• Low risk of bias: central allocation (including telephone, interactive voice-recorder, internet-based and pharmacy-controlled
randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.
• Unclear risk of bias: insufficient information about the allocation concealment.
• High risk of bias: used an open random allocation schedule (e.g. a list of random numbers); assignment envelopes used without
appropriate safeguards; alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.
We will also evaluate trial baseline data to incorporate assessment of baseline imbalance into the ’Risk of bias’ judgment for selection
bias (Corbett 2014). Chance imbalances may also affect judgments on the risk of attrition bias. In the case of unadjusted analyses,
we will distinguish between trials that we rate as being at low risk of bias on the basis of both randomisation methods and baseline
similarity, and trials that we judge as being at low risk of bias on the basis of baseline similarity alone (Corbett 2014). We will reclassify
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judgements of unclear, low or high risk of selection bias as specified in Appendix 3.
Blinding of participants and study personnel (performance bias due to knowledge of the allocated interventions by participants
and personnel during the trial)
We will evaluate the risk of detection bias separately for each outcome (Hróbjartsson 2013). We will note whether endpoints were
self-reported, investigator-assessed or adjudicated outcome measures (see below)
• Low risk of bias: blinding of participants and key study personnel was ensured, and it was unlikely that the blinding could have
been broken; no blinding or incomplete blinding, but we judge that the outcome is unlikely to have been influenced by lack of
blinding.
• Unclear risk of bias: insufficient information about the blinding of participants and study personnel; the trial does not address
this outcome.
• High risk of bias: no blinding or incomplete blinding, and the outcome is likely to have been influenced by lack of blinding;
blinding of trial participants and key personnel attempted, but likely that the blinding could have been broken, and the outcome is
likely to be influenced by lack of blinding.
Blinding of outcome assessment (detection bias due to knowledge of the allocated interventions by outcome assessment
We will evaluate the risk of detection bias separately for each outcome (Hróbjartsson 2013). We will note whether endpoints were
self-reported, investigator-assessed or adjudicated outcome measures (see below)
• Low risk of bias: blinding of outcome assessment is ensured, and it is unlikely that the blinding could have been broken; no
blinding of outcome assessment, but we judge that the outcome measurement is unlikely to have been influenced by lack of blinding.
• Unclear risk of bias: insufficient information about the blinding of outcome assessors; the trial did not address this outcome.
• High risk of bias: no blinding of outcome assessment, and the outcome measurement was likely to have been influenced by
lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome
measurement was likely to be influenced by lack of blinding.
Incomplete outcome data (attrition bias due to amount, nature or handling of incomplete outcome data)
For each included trial or each outcome, or both, we will describe the completeness of data, including attrition and exclusions from
the analyses. We will state whether the trial reported attrition and exclusions, and report the number of participants included in the
analysis at each stage (compared with the number of randomised participants per intervention/comparator groups). We will also note
if the trial reported the reasons for attrition or exclusion and whether missing data were balanced across groups or were related to
outcomes. We will consider the implications of missing outcome data per outcome such as high dropout rates (e.g. above 15%) or
disparate attrition rates (e.g. difference of 10% or more between trial arms)
• Low risk of bias: no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to introduce bias); missing outcome data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed
event risk was not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data,
plausible effect size (mean difference or standardised mean difference) among missing outcomes was not enough to have a clinically
relevant impact on observed effect size; appropriate methods, such as multiple imputation, were used to handle missing data.
• Unclear risk of bias: insufficient information to assess whether missing data in combination with the method used to handle
missing data were likely to induce bias; the trial did not address this outcome.
• High risk of bias: reason for missing outcome data was likely to be related to true outcome, with either imbalance in numbers
or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant bias in the intervention effect estimate; for continuous
outcome data, plausible effect size (mean difference or standardised mean difference) among missing outcomes enough to induce
clinically-relevant bias in observed effect size; ’as-treated’ or similar analysis done with substantial departure of the intervention
received from that assigned at randomisation; potentially inappropriate application of simple imputation.
Selective reporting (reporting bias due to selective outcome reporting)
We will assess outcome reporting bias by integrating the results of the appendix ’Matrix of trial endpoints (publications and trial
documents)’ (Boutron 2014; Jones 2015; Mathieu 2009), with those of the appendix ’High risk of outcome reporting bias according
to the Outcome Reporting Bias In Trials (ORBIT) classification’ (Kirkham 2010). This analysis will form the basis for the judgement
of selective reporting
• Low risk of bias: the trial protocol was available and all the trial’s prespecified (primary and secondary) outcomes that were of
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interest to this review were reported in the prespecified way; the study protocol was unavailable, but it was clear that the published
reports included all expected outcomes (ORBIT classification).
• Unclear risk of bias: insufficient information about selective reporting.
• High risk of bias: not all the trial’s prespecified primary outcomes were reported; one or more primary outcomes were reported
using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified; one or more reported
primary outcomes were not prespecified (unless clear justification for their reporting was provided, such as an unexpected adverse
effect); one or more outcomes of interest in the Cochrane Review were reported incompletely so that we cannot enter them in a
meta-analysis; the trial report failed to include results for a key outcome that we would expect to have been reported for such a trial
(ORBIT classification).
Other bias
• Low risk of bias: the trial appears to be free from other sources of bias.
• Unclear risk of bias: there was insufficient information to assess whether an important risk of bias existed; insufficient rationale
or evidence that an identified problem introduced bias.
• High risk of bias: the trial had a potential source of bias related to the specific trial design used; the trial was claimed to be
fraudulent; or the trial had some other serious problem.
Appendix 3. Selection bias decisions
Selection bias decisions for trials that reported unadjusted analyses: comparison of results obtained using method details








Risk of bias using baseline
information and methods re-
porting




Groups appear similar at base-
line for all important prognos-
tic variables
Low risk
Limited or no baseline details Unclear risk
Would generate a truly random
sample, with robust allocation
concealment




Groups appear similar at base-
line for all important prognos-
tic variables
Low risk
Limited baseline details, show-
ing balance in some important
prognostic variablesc
Low risk
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No baseline details Unclear risk
Sequence is not truly ran-
domised or allocation conceal-
ment is inadequate




Groups appear similar at base-
line for all important prognos-
tic variables
Low risk
Limited baseline details, show-
ing balance in some important
prognostic variablesc
Unclear risk
No baseline details High risk
aTaken from Corbett 2014; judgements highlighted in bold indicate situations in which the addition of baseline assessments would
change the judgement about risk of selection bias, compared with using methods reporting alone.
bImbalance identified that appears likely to be due to chance.
cDetails for the remaining important prognostic variables are not reported
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N O T E S
We have based parts of the Methods, as well as Appendix 1, Appendix 2 and Appendix 3 of this Cochrane Protocol on a standard
template established by the CMED group.
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